Kornimate/medical-research-clean huggingface dataset:
survey of dysmorphic uterus knowledge among gynecologists.

Conditions: Dysmorphic Uterus

Summary: uterine malformations were initially described by cruveilhier and von rokitansky in the 1800s. many proposed classifications had been presented over the years, although only two are mostly used worldwide: the first proposed by the american fertility society (afs) and the one recently published by european society on gynecologic endoscopy / european society of human reproductive endocrinology (esge/eshre). both classifications describe a special type of uterus, with an abnormally shaped narrow uterine cavity. this type of uterus was initially defined, before the use of ultrasound, as "hypoplasic uterus" by k. menge and k.v. oettingen in 1930. subsequently, the afs in its classification defined it as type vii as diethylstilbestrol-related and the esge/eshre classification defined it as class u1a or t-shaped uterus. at present there are no clear diagnostic criteria for this type of uterus and the only parameter widely accepted is that of "narrow uterine cavity due to thickened lateral walls". the purpose of this study is to conduct a survey of gynecologists in active clinical practice and resident (in training) gynecologists to establish the degree of concordance when cataloging 3d ultrasound images of normal or dysmorphic uteri, with the aim to identify common parameters that allow to identify the dysmorphic uterus with narrowing of the side walls. the study will be carried out in two stages: in an initial step, participants will complete a survey evaluating their knowledge of uterine malformations and their involvement in assisted reproduction in their current clinical practice. in the second step, participants will then watch a video of hysteroscopies and 3d ultrasound images of different cases highlighting the hysteroscopic/ultrasound correlation of the different variants of the uterus with narrowing of the side walls. each participant will be shown 40 (forty) 3d ultrasound images of uterus of normal women without infertility and 40 (forty) infertile women with uterus with narrowing in the middle third diagnosed by hysteroscopy + 3d ultrasound and associated infertility (in t, y or i shape). once the survey is finished, the degree of concordance will be evaluated, with the aim to identify common parameters of diagnosis of dysmorphic uterus by 3d ultrasound.


Eligibility criteria:
inclusion criteria: * practicing gynecologist specialist or fellow/resident (in training); * knowledge of the esge/afs and t-y-i uterine anomalies classification. exclusion criteria: • none.

Keywords: uterine malformations hysteroscopy 3d ultrasound infertility
ultrasound elastography in diffferentiation of endometriomas and hemorrhagic cysts

Conditions: Ovarian Endometrioma

Summary: to investigate the value of ultrasound elastography in differentiating endometriomas from ovarian hemorrhagic cysts

the participants will be subjected to: * personal, obstetric and gynecological history taking. * clinical examination. * b-mode ultrasonography was performed to characterize the adnexal masses morphologically. * color doppler ultrasound. * grayscale and elastographic ultrasound examination, which will be done using acoustic radiation force impulse (arfi) imaging with virtual touch quantification (vtq). five consecutive measurements were recorded for each lesion from the region identified as the region of interest (roi) and the median of these measurements was recorded as the shear wave velocity (swv) value of the lesion. in virtual touch quantification (vtq) the shear wave speed is expressed in m/s. only numerical results will be taken into consideration. . realtime elastographic and b-mode images simultaneously will appear as a two-panel image. elastogram appeared in the region of interest (roi) box to determine the target ovarian lesion and surrounding tissue, then elasticity colour code will be classified in 5 patterns : pattern 1, an absent or a very small hard area; pattern 2, hard area 45 per cent; pattern 4, peripheral hard and central soft areas; pattern 5, hard area occupying entire solid component with or without soft rim. strain index will be analyzed, which will be obtained by comparing the absolute strain value of solid component of ovarian cyst with that of surrounding soft tissue. * the invistigator will reevaluate the lesions 4 weeks after the initial assessment to see the possible changes in the size and/or configuration of the lesions with b-mode and elastographic ultrasonography. * lesion will be evaluated as endometriomas and referred for surgery when shows no significant changes in size and configuration. * hemorrhagic cyst diagnosis will be made if the lesion had resolved on follow-up.

Eligibility criteria:
inclusion criteria: * patient suspected to have endometrioma or hemorrhagic ovarian cysts. exclusion criteria: * simple cysts which were defined as a sonolucent thin-walled (\<3 mm thick) cyst larger than 3 cm in diameter without septations or papillary projections \[12\]. * hemorrhagic cysts containing septations or mural nodules with detectable flow on doppler ultrasonography

Keywords: ultrasound elastography
does saxagliptin reduce the risk of cardiovascular events when used alone or added to other diabetes medications

Conditions: Type 2 Diabetes Mellitus

Summary: the purpose of this study is to determine whether saxagliptin can reduce the risk of cardiovascular events when used alone or added to other diabetes medications

a multicentre, randomised, double-blind, placebo-controlled phase iv trial to evaluate the effect of saxagliptin on the incidence of cardiovascular death, myocardial infarction or ischaemic stroke in patients with type 2 diabetes

Eligibility criteria:
inclusion criteria: * patients with type 2 diabetes mellitus * hba1c ≥6.5%. (based on the last measured and documented laboratory measurement within 6 months) * high risk for cv events -established cardiovascular disease and/or multiple risk factors exclusion criteria: * current or previous (within 6 months) treatment with dpp4 inhibitors and/or glp-1 mimetics * acute vascular event \<2months prior to randomisation

Keywords: risk of cardiovascular disease and death in patients with type 2 diabetes mellitus
magnetomotoric ultrasound (mmus) in rectal cancer

Conditions: Rectal Cancer

Summary: magnetomotoric ultrasound, combines conventional ultrasound with a time-varying magnetic field. the aim is to improve diagnosis of mesolectal lymph nodes.

magnetomotoric ultrasound, combines conventional ultrasound with a time-varying magnetic field. nanoparticles are injected close to the rectal cancer and migrate to adjacent lymph nodes.the time-varying magnetic field will influence the nano particles in the lymph node enhancing diagnosis of affected lymph nodes. the aim is to improve diagnosis of mesolectal lymph nodes and compare the results of magnetomotoric ultrasound with mri and final histopathology.

Eligibility criteria:
inclusion criteria: * rectal cancer * scheduled for total mesorectal surgery * informed consent exclusion criteria: * not able to give informed consent * synchronus colorectal cancer
study to evaluate glaxosmithkline (gsk) biologicals' menc-tt vaccine and hib-menc-tt vaccine in infants

Conditions: Infections, Meningococcal

Summary: the purpose of this primary vaccination study is to evaluate the immunogenicity, safety and reactogenicity of three doses of gsk biologicals' menc-tt (neisseria meningitidis group c polysaccharide-tetanus toxoid) vaccine (2 different formulations) and of three doses of gsk biologicals' hib-menc-tt (haemophilus influenzae type b-menc-tt) vaccine (2 different formulations) when given to infants in their 3rd, 4th, and 5th months of life. concomitant vaccines were given to all children to complete the vaccination agenda.

five parallel treatment groups receiving a 3-dose primary vaccination course: menc-tt vaccine (2 formulations, double-blind) + infanrix hexa® or hib-menc-tt (2 formulations double-blind) + infanrix penta® or meningitec™ + infanrix hexa® (control). three blood samples taken, before dose 1 and one month after dose 2 and dose 3.

Eligibility criteria:
inclusion criteria: * healthy male or female infants, 8 to 16 weeks of age at the time of the first vaccination. exclusion criteria: * previous vaccination against or history of or exposure since birth to diphtheria, pertussis, tetanus, polio, hepatitis b, hib and/or meningococcal disease. * planned administration/administration of a vaccine not foreseen in the study since birth. * any confirmed or suspected immunosuppressive or immunodeficient condition, including human immunodeficiency virus (hiv) infection. * a family history of congenital or hereditary immunodeficiency. * history of any neurologic disorders or seizures, allergic disease or reactions likely to be exacerbated by any component of the vaccine

Keywords: haemophilus influenzae type b/meningococcal vaccine prophylaxis meningococcal serogroup c disease, hib diseases
study to explore morbimortality in patients dialyzed with the theranova hdx in comparison to on-line-hemodiafiltration

Conditions: Chronic Kidney Disease Requiring Chronic Dialysis

Summary: study to evaluate the safety and efficacy of expanded hemodialysis (hdx) compared to hemodiafiltration (hdf) in patients with chronic kidney disease in spain for up to 36 months. approximately 700 patients will be included.

this is an open-label, prospective, 1:1 randomized, parallel-group, study to evaluate the safety and efficacy of expanded hemodialysis (hdx) compared to hemodiafiltration (hdf) in patients with chronic kidney disease in spain for up to 36 months. stable incident hemodialysis patients from hemodialysis in-hospital units and related satellite centers in spain.

Eligibility criteria:
inclusion criteria: * end stage renal disease (esrd) patients * age\> 18 years old * hd therapy three times per week for 3 months at least and a maximum of 24 months. exclusion criteria: * no informed consent provided * synthetic membrane allergy * pregnant, breastfeeding, or planning to become pregnant * active systemic diseases: liver cirrhosis, malignancy prior to enrollment (except basal cell skin or similar) and / or immunosuppressive treatment in the 3 months before the recruitment. * scheduled for living-donor transplantation within the study period * patients with a significant residual renal function (defined as urea clearance \>2,5 ml/min. * currently participating in another interventional clinical study or has participated in another interventional clinical study in the last 3 months that may interfere with this study.
the effect of platelet rich plasma on partial thickness rotator cuff tears: a randomized controlled trial

Conditions: Rotator Cuff Injuries

Summary: randomized controlled trial examining platelet rich plasma versus corticosteroid injection in partial thickness rotator cuff tears or tendinopathy.

we performed a randomized controlled trial on patients with imaging-shown rotator cuff tendinopathy or partial thickness tearing. patients were randomized to receive either platelet rich plasma or corticosteroid. follow-up was done at 6 weeks, 3 months and 12 months following injection.

Eligibility criteria:
inclusion criteria: * \>18 years * mri or us evidence of supraspinatus tendinopathy or partial thickness tearing * symptomatic for minimum of 3 months * patient has exhausted a course of adequate conservative treatment (including but not limited to home/out patient physical therapy, oral analgesics, and/or shoulder injections) exclusion criteria: * prior surgical intervention on affected shoulder * full thickness rotator cuff tear * concomitant ipsilateral shoulder pathology (i.e. osteoarthritis, inflammatory arthritis) * confounding cervical neck pain or radiculopathy * more than 3 previous cs injections * a cs injection within 6 months of study intervention * elite level athlete * worker's compensation case * litigation or secondary gain issues * unwilling or unable to provide informed consent or complete study outcomes

Keywords: corticosteroid platelet rich plasma tendinopathy partial thickness tear
biospecimen repository for cardiac arrhythmias at the cleveland clinic

Conditions: Arrhythmias, Cardiac

Summary: biorepository of blood and or tissue samples from patients presenting with cardiac arrhythmia syndromes.

the long-term objective of this research is to find genes and biologic pathways causing arrhythmia syndromes and other diseases or conditions. in order to achieve this objective the investigators will collect comprehensive phenotypic data and corresponding blood and/or tissue samples into a biorepository registry of patients, presenting for cardiac arrhythmia evaluation and/or treatment, and control subjects without arrhythmias. this biorepository will be composed of two parts: 1) an arrhythmia biorepository of blood and tissue from patients undergoing arrhythmia procedures, cardiac surgery, or inpatient or outpatient evaluations for arrhythmias, and 2) a collaborative sample biorepository for de-identified samples and data from outside institutions and clinical trials.

Eligibility criteria:
inclusion criteria: * male or female at least 18 years old * subjects with a history of or current cardiac arrhythmia, family members of subjects with cardiac arrhythmias, or no cardiac arrhythmia if a control subject. exclusion criteria: * subjects previously enrolled in the arrhythmia biobank

Keywords: genetics biorepository cardiac death atrial fibrillation ventricular fibrillation ventricular tachycardia supraventricular tachycardias premature ventricular complexes premature atrial complexes atrioventricular and intraventricular blocks sinus node dysfunction syncope vasovagal reactivity postural orthostatic tachycardia syndrome
serious game to teach opioid overdose response

Conditions: Opioid Overdose

Summary: this study evaluates the efficacy of a serious game to teach students how to recognize and respond to opioid overdose

this study uses an interactive realistic film depicting an opioid overdose to teach high school/middle school students how to recognize and respond to opioid overdose. the film features a person who finds their friend unresponsive, with evidence of opioid use. the unresponsive friend demonstrates signs of opioid overdose. the hero must recognize opioid overdose, administer naloxone (opioid antedote) and perform cpr. the film is made interactive by the narrator pausing the action of the film, and asking learners to answer questions/make choices. efficacy is tested on the day of training, and 2-4 months later. efficacy is measured by student ability to correctly administer naloxone to a manikin, perform cpr, and answer knowledge questions about opioid overdose. other studied metrics include student engagement/enjoyment, attitudes/biases, and emotions created by the training. these will be tested through validated questionnaires.

Eligibility criteria:
inclusion criteria: * student at participating school, enrolled in health or science class exclusion criteria: * none
comparisons of 3-month versus 6-month solifenacin treatment for female oab patients

Conditions: Overactive Bladder Syndrome

Summary: to investigate whether prolonged period of treatment (6 months) can have a better therapeutic outcome than conventional period (3 months) of antimuscarinics.

overactive bladder syndrome (oab), with or without urge incontinence, is characterized by urinary urgency, frequency and nocturia. thus, patients with oab could be considered to have a reduced quality of life. patients with overactive bladder syndrome have a higher risk of falling and fracture due to nocturia. oab affects around 17 % of female population. at present, muscarinic receptor antagonists are the ﬁrst-line pharmacotherapeutic agents for oab. however, discontinuation of the treatment often results in symptom relapse. until now, optimal duration of the treatment and durability of the efﬁcacy have not been determined. we plan to use urodynamic studies outcome to evaluate therapeutic effect, with the change of urinary nerve growth factor level. this study is a randomized prospective study, comparing female oab patient after 3 months and 6 months of antimuscarinic treatment. the purpose of this study is to investigate the difference of urodynamic effects, therapeutic effect and urinary urinary nerve growth factor level between oab females after 3 months and 6 months antimuscarinic treatment.

Eligibility criteria:
inclusion criteria: * women who have overactive bladder syndrome exclusion criteria: * women who are less than 20 year-old

Keywords: antimuscarinic treatment urodynamic studies nerve growth factor
reduction of inappropriate shocks of implantable cardioverter defibrillators (icds) with enhanced svt discriminators

Conditions: Tachycardia

Summary: the purpose of this clinical investigation is the continued assessment of the decision accuracy of st. jude medical (sjm) icd with enhanced svt discriminators in the treatment of subjects with primary and secondary prevention of sudden cardiac death.

with ellipse™ and fortify assura™ icd family, st. jude medical introduced enhanced device algorithms that may be helpful to further improve svt discrimination success: securesense™, far field morphology, chamber onset. these algorithms in combination with a tailored device setting (primary or secondary prevention) will be prospectively investigated within this trial.

Eligibility criteria:
inclusion criteria: * ischemic or nonischemic cardiomyopathy * primary prevention or secondary prevention of sudden cardiac death (scd) * indication for icd/crt-d new implantation per current guidelines (1, 2, 3-chamber) * the patient is ≥ 18 years of age * the patient is able to understand the patient information and is capable to provide informed consent. * the patient has provided written informed consent prior to any investigational related procedure exclusion criteria: * previously implanted icd/crt-d * hypertrophic (with or without obstructive) cardiomyopathy * ion channel disorders (long/short-qt, brugada syndrome etc...) * new york heart association (nyha) class iv * recent cardiac decompensation (within previous 3 months) * the patient is unable to comply with the follow up schedule. * the patient is participating in another investigational device or drug investigation. * the patient is pregnant or is planning to become pregnant during the duration of the investigation

Keywords: icd crt-d sudden cardiac death device settings optimized programming strategy
the efficacy of hemp-containing cream versus placebo in the treatment of uremic pruritus

Conditions: Uremic Pruritus

Summary: uremic pruritus is a significant burden on hemodialysis patients, affecting approximately 46% of individuals undergoing dialysis. various mechanisms, including inadequate dialysis, increased uremic toxins, inflammatory cytokines, parathyroid hormone, phosphorus, dry skin, mast cell histamine secretion, and nerve stimulation through μ-opioid receptors and nociceptors, contribute to uremic pruritus. current treatments include antihistamines, gabapentin, moisturizer creams, and capsaicin creams, with limited success, as only 10% of patients find relief. cannabinoids were also mentioned in uremic pruritus treatment but are less commonly used and there are no randomised controlled trial. cannabinoid binding to cb1 and cb2 receptors inhibits mast cell differentiation, aggregation, and histamine release, whereas cannabinoid binding to trp-iron receptors reduces peripheral nerve activation. thus, cannabinoid seem to effective in relieving pruritus via various mechanisms. this study aims to assess the effectiveness of a hemp-containing cream in comparison to a placebo for treating uremic pruritus among hemodialysis patients.

eligible participants is randomly assigned in a 1:1 ratio to receive either a hemp-containing cream or a placebo. then, they are assessed for the severity of itching symptoms using the wi-nrs and their itch-related quality of life using the skindex-10 score at baseline, week 2, and week 4 of the study. additionally, adverse effects are documented. data is collected by the research assistant and recorded in computer with locking password and also was validated with second assistant. we planned for a sample size of 60 participants to detect differences in itchineligible participants is randomly assigned in a 1:1 ratio to receive either a hemp-containing cream or a placebo. then, they are assessed for the severity of itching symptoms using the wi-nrs and their itch-related quality of life using the skindex-10 score at baseline, week 2, and week 4 of the study. additionally, adverse effects are documented. data is collected by the research assistant and recorded in computer with locking password and also is validated with second assistant. for statistical analysis, continuous variables are compared using an unpaired t-test or mann-whitney u test, as appropriate. categorical variables are compared using a chi-square test or fisher's exact test. the adjusted mean difference is used analysis of covariance (ancova) , adjusted by score at baseline. all statistical analyses were performed using stata v.17.0 (statacorp, texas).

Eligibility criteria:
inclusion criteria: * adults ≥ 18 years old, diagnosed with end-stage kidney disease * undergoing thrice-weekly chronic hemodialysis for more than 90 days * exhibit a wi-nrs score of 3 or higher exclusion criteria: * ahistory of hemp allergy * pregnancy or breastfeeding * dermatologic diseases * adjustments to medications for controlling itch within the 14 days preceding the study.

Keywords: hemp uremic pruritus hemodialysis cannabinoid